EP0587676A1 - A mouse immunoglobulin heavy-chain locus enhancer which crosshybridizes with the 3'-enhancer element of rat - Google Patents
A mouse immunoglobulin heavy-chain locus enhancer which crosshybridizes with the 3'-enhancer element of ratInfo
- Publication number
- EP0587676A1 EP0587676A1 EP19920911653 EP92911653A EP0587676A1 EP 0587676 A1 EP0587676 A1 EP 0587676A1 EP 19920911653 EP19920911653 EP 19920911653 EP 92911653 A EP92911653 A EP 92911653A EP 0587676 A1 EP0587676 A1 EP 0587676A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- enhancer
- igh
- mouse
- rat
- dna
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/30—Vector systems having a special element relevant for transcription being an enhancer not forming part of the promoter region
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/80—Vector systems having a special element relevant for transcription from vertebrates
- C12N2830/85—Vector systems having a special element relevant for transcription from vertebrates mammalian
Definitions
- a mouse immurioglobulin heavy-chain locus enhancer which crosshybridizes with the 3' -enhancer element of rat.
- the present invention concerns a novel DNA 4kb/Xba I fragment and novel DNA seguence with lymphoid-specific transcription enhancing properties.
- the present invention further concerns an eukaryotic immunoglobulin expression vector comprising the novel enhancer.
- immunoglobulin gene is controlled by lympho- id-specific enhancer elements acting in concert with lymphoid- specific promoters.
- a moderately weak enhancer was initially identified in the J ⁇ -C ⁇ intron [1, 2]; subseguently, a second, stronger enhancer was discovered 3' of the C x exon [3]. It transpires that it is the 3'-enhancer which plays a critical role in ensuring the high level expression of rearranged ⁇ genes [4, 5].
- the intron- enhancer appears to be involved in the regulation of V ⁇ -J ⁇ joining.
- BSTITUTESHEET homologous to that of the rat both as regards sequence and organization although the enhancer is present in the two species in opposite orientations.
- its inclusion stimulates expression of rearranged ⁇ genes that have been stably transfected into a plasmacytoma host.
- a recombinant DNA molecule comprising the novel enhancer described above, having at least part or parts of the sequence given in Figure 3.
- the molecule may additionally comprise other elements, and will generally further comprise a promoter and a gene or genes coding for a protein or proteins of interest.
- the novel enhancer may be used to enhance expression of genes in host cells, in vivo and in vitro, particularly in certain lymphoid cell lines and in transgenic animals.
- the novel enhancer may further be used for the production of monoclonal antibodies.
- novel.enhancer is B-cell specific it may be used to target tissue specific expression of genes. This property means the enhancer potentially finds particular use in certain therapeutic applications, for targeting production of proteins, and in hybridoma technology.
- sequence of the novel enhancer may be derived by recom ⁇ binant DNA techniques from a naturally occurring gene system or may correspond to a naturally occurring gene system in the sense of being manufactured using known techniques of poly- nucleotide synthesis from sequence data relating to a naturally occurring gene system. Alterations of the sequence may be made which do not alter the function of the enhancer.
- the invention also provides a vector for the integration of a gene into the genetic material of a hosT cell such that the gene may be expressed by the hosT cell, the vector comprising
- Filters of a cosmid library were generated by cloning sheared BALB/c mouse liver DNA into the Bam HI site of cosmid pWE15.
- DNA of cosmid Cos37-l-l which includes rat C a and the rat IgH 3'-enhancer [13].
- DNA sequen- cing was carried out by the chain termination method using Sequenase * (USB, Cleveland, OH) .
- the cell line PC 11 3U4 obtained from B. Wasylyk, LGME, France
- NSO 14
- HeLa from our laboratory collection
- HOPC-1 [15]
- A20 and M12 cells [16] were cultured in DMEM/10% FCS containing 50 ⁇ M 2-ME.
- test plasmids were constructed from pUC12 derivatives that contained the human ⁇ -globin gene from 128 nucleotides upstream of the transcription start to the Pst I site downstream of the coding sequence cloned between the Xba I and Pst I sites of the polylinker.
- Enhancer fragments to be assayed were introduced between the Sac I and Xba I sites upstream of the gene.
- the internal reference was provided by plasmid ⁇ SVHP ⁇ 2 [19] which contains the human ⁇ 2 ⁇ gl°- D;Ln gene.
- Total cytoplasmic RNA was prepared from cells 30-36 h after transfection and assayed by ribonuclease protection assays as previously described [3].
- Transfectants of NSO that carry a long or short transfected ⁇ gene in a pSV2neo-based vector have been described previously [5]; these cells were super- transfected with pSV2gpt-based plasmids that contained a rearranged mouse ⁇ gene (pSV-V ⁇ l; [20]) or a derivative of pSV- V ⁇ l which includes the Stu I fragment of the mouse IgH 3'- en ancer cloned into the plasmid's unique Xho I site.
- FIG 1 shows alignment of the 5'-repeat with the invert of the 3'-repeat of the rat enhancer. Nucleotide posi ⁇ tions are numbered as in Fig. 3 and positions of identity are indicated by an asterisk.
- B shows invert repeats in the rat IgH 3'-enhancer. Sequences of at least 12 bases of invert identity are joined by a line. The enhancer core lies within the Stu I-Eco RV fragment (indicated by a line) whose sequence was determined previously [5].
- C shows invert repeats in the mouse IgH 3'-enhancer.
- (D) shows southern blot of Ba un ⁇ digested genomic mouse DNA hybridized with a probe that in- eludes the repeat flanking the mouse IgH 3'-enhancer (the Eco RI-Apa LI fragment depicted as probe A in Fig. 4; nucleotides 55-748 in the mouse IgH 3'-enhancer sequence).
- DNA was either from mouse liver or from the MOPC315 or J558L plasmacytomas. The filter was washed at 65°C in 2 x SSC.
- Figure 2 shows the map of the mouse IgH locus and of regions present in cosmid and phage clones.
- Figure 3 shows the sequences of mouse (A) and rat (B) IgH 3'- enhancers of the invention.
- Probes A, B, C and F are Eco RI-Apa LI, Stu I- Xba I, Xba I-Pst I and Sac I subfragments of phage ⁇ M2 whereas probes D and E were obtained as Eco RI-Bgl I (nucleotides 565- 740) and Ace I-Eco RI (nucleotides 431-565) subfragments of the rat IgH 3'-enhancer over a region where the mouse and rat enhancers are highly homologues.
- (B) is the map of the rat C ⁇ /IgH 3'-enhancer region. Cosmid 37-1-1 DNA was digested with
- SUBSTITUTESHEET various restriction endonucleases and hybridized as indicated. Restriction sites are abbreviated C. Cla I; N, Nru I; R, Eco RI; S, Sac I; X, Xho I.
- Figure 5 shows that the mouse IgH 3'-enhancer exhibits lympho ⁇ id-specific transcriptional activity.
- Cells were transfed with a test plasmid containing the human 0-globin gene linked to the SV40, rat IgH-intron, mouse IgH-intron, mouse IgH-3' or no enhancer as indicated along with and ⁇ 2 -globin plasmid as internal reference.
- Markers (M) were provided by a Hpa II digest of pBR322.
- the IgH 3'-enhancer is flanked by an invert repeat.
- the sequen ⁇ ce of the Stu I-Eco RV fragment of the rat 3'-enhancer has been determined previously [12].
- the sequence of the invention does indeed confirm the existence of flanking invert repeats (Fig. 1) . These repeats show 16 mismatches over a 357- bp stretch (> 95% identity) .
- a mouse liver library in bacteriophage ⁇ was therefore screened using as a probe an Ace I-Bgl I subfragment from the core of the rat 3'-enhancer (nucleotides 432-748 in the rat sequence; see Fig. 4) .
- Two overlapping groups of clones ( ⁇ M2 and ⁇ M3) were isolated.
- the restriction map of ⁇ M2 is depicted in Fig. 2; phage ⁇ M3 extends 3' of ⁇ M2.
- the Xba I fragment of ⁇ M2 that contained the enhancer homology was subcloned into plasmid pIC20H; a processive set of dele-
- SUBSTITUTE SHEET tions was made using exonuclease III and subcloned into M13.
- the sequence of the mouse IgH 3'-enhancer was determined as is shown in Fig. 3 where it is aligned with that of the rat.
- the enhancer of the two species show good homology although the [GT] 7 [ (G or C)A] 89 ] repeat of the rat is not observed in the mouse.
- the invert repeats that flank the ra IgH 3'-enhancer show a 96% identity
- the internal 250 nucleoti des of the equivalent mouse repeats manifest only 89% identity (Fig. 1C) .
- the octanucleotide element ATTTGCAT is conserved in rat and mouse.
- SUBSTITUTE SHEET phage ⁇ M2 shows that the 3'-enhancers of mouse and rat were present in the genome in opposite orientations with respect to the IgH C-regions. To confirm that this was not a cloning artefact, a Southern blot analysis of genomic mouse DNA was carried out. The core region of the enhancer in rat and mouse contains a conserved Eco RI site. In genomic mouse plots, probes F and C hybridize to a 12-kb Eco RI fragment whereas probes B and E hybridize to a 2-kb Eco RI fragment (Fig. 4A) .
- probe E lights up the C ⁇ -distal side of the Eco RI site in the mouse 3'-enhancer.
- probe E is an Ace I-Eco RI subclone of the rat 3'-enhancer and derives from a region (nucleotides 432-565) which is located on the C ⁇ -proximal side of the Eco RI site within the rat 3'- enhancer [12]. This is confirmed in Fig.
- the 4 kb/Xba I fragment was linked to an enhancerless human ⁇ -globin gene and introduced into MPCll mouse plasmacytoma cells along with an ⁇ 2 -globin gene as internal reference.
- the IgH 3'-enhancer (like the SV40 and IgH intron-enhancers) does indeed potentiate 3-globin expression in the transfected myeloma cells.
- the IgH 3'-enhancer is inactive in HeLa cells.
- the mouse IgH 3'-enhancer appears lymphoid-specific.
- mice plasmacytoma cells was transfected with plasmid pSV-Vl, which contains a rearranged ⁇ gene including the IgH intron-enhancer, and a derivative, pSV-Vl[3'E] , which also includes the IgH 3'- enhancer cloned downstream of the transcription unit.
- NSO cells that had been previously transfected with one of two plasmids encoding a mouse ⁇ chain.
- the NSO[S ⁇ ] cells carry a transfected ⁇ gene that includes the ⁇ -intron but not the ⁇ 3' -enhancer whereas the transfected gene in the NS0[L ⁇ ] cells includes both the ⁇ -intron and the ⁇ 3 ' - enhancers [5].
- Northern blot analysis of pools of transfected cells Fig. 6) reveals that inclusion of the IgH 3'-enhancer on plasmid pSV-V ⁇ l has about a sixfold effect on the level, of ⁇ gene expression in the transfected cells.
- the mouse also contains a lymphoid-specific enhancer located downstream of the C H regions.
- the enhancer in both species is flanked by an invert repeat.
- certain differences between rat and mouse in the sequences of the upstream copy of their repeats are also found in the downstream copy.
- nucleotides 574-578 (CATGA) in the mouse upstream repeat are not present in the rat; similarly, the invert of this sequence (TCATG) is retained in the downstream copy of the mouse repeat but is nevertheless still absent in the rat.
- the flanking repeats appear to have co-evolved with information transfer between the two such that some changes that occur in the upstream repeat also become fixed in the downstream copy.
- vector as used herein connotes in its broadest sense any recombinant DNA material capable of transferring DNA from one cell to another.
- the vector may be a single piece of DNA in linear or circular form an may, in addition to the essential functional elements of the invention, include such other sequences as are necessary for particular applications.
- the vector may be a single piece of DNA in linear or circular form an may, in addition to the essential functional elements of the invention, include such other sequences as are necessary for particular applications.
- the vector may be a single piece of DNA in linear or circular form an may, in addition to the essential functional elements of the invention, include such other sequences as are necessary for particular applications.
- the vector may be a single piece of DNA in linear or circular form an may, in addition to the essential functional elements of the invention, include such other sequences as are necessary for particular applications.
- the vector may be a single piece of DNA in linear or circular form an may, in addition to the essential functional elements of the invention, include such other sequences as are necessary for particular applications.
- the vector may be a single piece of DNA in linear or circular form an may, in addition to the essential functional elements of the invention, include such other sequences as are necessary for particular
- SUBSTITUTE SHEET contain additional features such as a selectable marker gene o genes, and/or features which assist translation or other aspects of the production of a cloned product.
- the term "gene” as used herein connotes a DNA sequence, prefe ⁇ rably a structural gene encoding a polypeptide.
- the polypeptid may be a commercially useful polypeptide, such as a pharmaceu ⁇ tical and may be entirely heterologous to the host cell.
- the gene may encode a polypeptide which is deficient, absent or mutated in the host cell.
- the host cell may be any host cell susceptible to uptake of th vector of the invention.
- the vector DNA may be transferred to the host cell by transfection, infection, microinjection, cell fusion, or protoplast fusion.
- the host cell may be a cell of a living human or animal.
- the host cell may be a cell of a transgenic animal such as a mouse.
- the host cell may be a human stem cell such a bone marrow cell.
- the promoter may be any promoter capable of functioning ' in the host cell and may be for example a mammalian or viral promoter.
- the invention also includes within its scope a host cell, e g of a cell line or a transgenic animal, transformed with a vector according to the invention.
- the invention further provides a method of producing a polypep tide, comprising culturing a host cell transformed with a vector according to the invention.
- the method may be applied in vitro to produce a desired poly ⁇ peptide.
- the method may be applied in vivo to produce a polypeptide having no therapeutic value to the animal.
- the vector may be used in
- SUBSTITUTE SHEET a method of treatment of the human or animal body by replacing or supplementing a defective gene.
- a method of gene therapy comprising removing ste cells from the body of a human or an animal, killing stem cells remaining in the body, transforming the removed stem cells with a vector of the invention containing a gene-defici ⁇ ent, or absent, in the human or animal body, and replacing the transformed stem cells in the human or animal body.
- This method can be used to replace or supplement a gene deficient in a human or animal.
- Bone marrow is a suitable source of stem cells and is advanta- geous in that it contains the precursors of both lymphocytes and erythroid cells.
- tissue could be removed from the body, transfected or otherwise provided with a vector of the invention and implanted back into the body.
Abstract
Fragment 4kb/Xba I d'ADN qui est un activateur 3' de l'IgH, ledit fragment ayant été obtenu en clonant un condensé Sau 3AI partiel d'ADN BALB/c de foie de souris dans le vecteur lambda 2001 et s'hybridant de manière croisée avec l'élément activateur 3' du rat. La présente invention concerne en outre une nouvelle séquence d'ADN possédant des propriétés d'activation de la transcription spécifique lymphoïde ainsi qu'un vecteur d'expression de l'immunoglobuline eucaryote qui contient ledit activateur 3' de l'IgH.4kb / Xba I fragment of DNA which is a 3 'activator of IgH, said fragment having been obtained by cloning a partial Sau 3AI condensate of BALB / c DNA from mouse liver in the lambda 2001 vector and hybridizing crossed with the activating element 3 'of the rat. The present invention further relates to a new DNA sequence having activation properties of specific lymphoid transcription as well as to an expression vector of the eukaryotic immunoglobulin which contains said activator 3 ′ of IgH.
Description
Claims
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE9101740 | 1991-06-07 | ||
SE9101740A SE9101740L (en) | 1991-06-07 | 1991-06-07 | NEW DNA FRAGMENTS AND SEQUENCES |
Publications (1)
Publication Number | Publication Date |
---|---|
EP0587676A1 true EP0587676A1 (en) | 1994-03-23 |
Family
ID=20382963
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP19920911653 Withdrawn EP0587676A1 (en) | 1991-06-07 | 1992-06-03 | A mouse immunoglobulin heavy-chain locus enhancer which crosshybridizes with the 3'-enhancer element of rat |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP0587676A1 (en) |
JP (1) | JPH06508514A (en) |
SE (1) | SE9101740L (en) |
WO (1) | WO1992021762A1 (en) |
-
1991
- 1991-06-07 SE SE9101740A patent/SE9101740L/en not_active Application Discontinuation
-
1992
- 1992-06-03 JP JP4510825A patent/JPH06508514A/en active Pending
- 1992-06-03 EP EP19920911653 patent/EP0587676A1/en not_active Withdrawn
- 1992-06-03 WO PCT/SE1992/000375 patent/WO1992021762A1/en not_active Application Discontinuation
Non-Patent Citations (1)
Title |
---|
See references of WO9221762A1 * |
Also Published As
Publication number | Publication date |
---|---|
WO1992021762A1 (en) | 1992-12-10 |
SE9101740D0 (en) | 1991-06-07 |
SE9101740L (en) | 1992-12-08 |
JPH06508514A (en) | 1994-09-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP3102697B2 (en) | Improvements in or related to enhancers | |
AU756620B2 (en) | Mutations in the myostation gene cause double-muscling in mammals | |
Li et al. | Regulation of the PU. 1 gene by distal elements | |
Jorcyk | The human ETS1 gene: genomic structure, promoter characterization and alternative splicing | |
Echaniz-Laguna et al. | The promoters of the survival motor neuron gene (SMN) and its copy (SMNc) share common regulatory elements | |
Flenniken et al. | Developmental expression of the endogenous TIMP gene and a TIMP-lacZ fusion gene in transgenic mice. | |
Taketani et al. | The human protoporphyrinogen oxidase gene (PPOX): organization and location to chromosome 1 | |
US5888765A (en) | Endothelial-cell specific promoter | |
US6524851B1 (en) | Hybrid nucleic acid molecules and vectors including β-globin regulatory elements | |
Cartwright et al. | The human nerve growth factor gene: structure of the promoter region and expression in L929 fibroblasts | |
Slater et al. | Glucocorticoid receptor binding site in the mouse alpha-amylase 2 gene mediates response to the hormone. | |
Manabe et al. | Isolation of the embryonic form of smooth muscle myosin heavy chain (SMemb/NMHC-B) gene and characterization of its 5′-flanking region | |
Ishida et al. | Genomic organization and promoter analysis of the Dnmt3b gene | |
Paciucci et al. | Dissection of the mouse N-ras gene upstream regulatory sequences and identification of the promoter and a negative regulatory element | |
Macleod et al. | A promoter trap in embryonic stem (ES) cells selects for integration of DNA into CpG islands | |
Troyanovsky et al. | Activation of the silent human cytokeratin 17 pseudogene‐promoter region by cryptic enhancer elements of the cytokeratin 17 gene | |
EP0669977A1 (en) | Transformed endothelial cells | |
Thatikunta et al. | Reciprocal Id expression and myelin gene regulation in Schwann cells | |
EP0587676A1 (en) | A mouse immunoglobulin heavy-chain locus enhancer which crosshybridizes with the 3'-enhancer element of rat | |
JPH0568560A (en) | Gene of bovin myogenic factor | |
US20100107265A1 (en) | Double-muscling in mammals | |
Collins | Retinoic acid-induced differentiation of retrovirus-infected HL-60 cells is associated with enhanced transcription from the viral long terminal repeat | |
US6303370B1 (en) | Tissue-specific regulatory elements | |
Lee et al. | Transcriptional promoter of the human α 1 (V) collagen gene (COL5A1) | |
Kaushansky et al. | The regulation of GM-CSF is dependent on a complex interplay of multiple nuclear proteins |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 19931210 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB IT LI NL SE |
|
17Q | First examination report despatched |
Effective date: 19970327 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 19971008 |